Robert Lakin

Robert Lakin

InvestorPlace Contributor

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

RIDE Stock: Why Lordstown Motors Shares Are Accelerating Today

By Robert Lakin, InvestorPlace Contributor

After a short-seller report knocked the wind out of RIDE stock on Friday, Lordstown Motors shares are on the mend. It promised a full production report along with its March 17 earnings announcement.

SNDL Stock: Sundial Growers Pops on New Joint Venture Plans

By Robert Lakin, InvestorPlace Contributor

SNDL stock is active in Monday's pre-market on news of a new JV that could lead to a Canadian SPAC transaction.

SNDL Stock: One Analyst Just Gave Sundial Growers A Big Boost

By Robert Lakin, InvestorPlace Contributor

Cantor Fitzgerald initiated coverage of SNDL stock, giving the shares of the Canadian cannabis company a "neutral" rating and a target some 18% below current levels.

MNOV Stock: MediciNova Soars on Big BARDA Deal

By Robert Lakin, InvestorPlace Contributor

MediciNova's MN-166 lung treatment is the first to get BARDA funding for repurposing research. MNOV stock double in Wednesday's premarket following that announcement.

INVO Stock: Why INVO Bioscience Is Skyrocketing Today

By Robert Lakin, InvestorPlace Contributor

INVO stock is on the move Tuesday after INVO Bioscience announced plans to expand its fertility clinic footprint.

Load More